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Transcriptional regulatory networks underlying
gene expression changes in Huntington’s disease
Seth A Ament1,2,†, Jocelynn R Pearl1,3,4,†, Jeffrey P Cantle5, Robert M Bragg5, Peter J Skene6,
Sydney R Coffey5, Dani E Bergey1, Vanessa C Wheeler7, Marcy E MacDonald7, Nitin S Baliga1 ,
Jim Rosinski8, Leroy E Hood1, Jeffrey B Carroll5 & Nathan D Price1,*
Abstract
Transcriptional changes occur presymptomatically and through-
out Huntington’s disease (HD), motivating the study of transcrip-
tional regulatory networks (TRNs) in HD. We reconstructed a
genome-scale model for the target genes of 718 transcription
factors (TFs) in the mouse striatum by integrating a model of
genomic binding sites with transcriptome profiling of striatal
tissue from HD mouse models. We identified 48 differentially
expressed TF-target gene modules associated with age- and CAG
repeat length-dependent gene expression changes in Htt CAG
knock-in mouse striatum and replicated many of these associa-
tions in independent transcriptomic and proteomic datasets.
Thirteen of 48 of these predicted TF-target gene modules were
also differentially expressed in striatal tissue from human
disease. We experimentally validated a specific model prediction
that SMAD3 regulates HD-related gene expression changes using
chromatin immunoprecipitation and deep sequencing (ChIP-seq)
of mouse striatum. We found CAG repeat length-dependent
changes in the genomic occupancy of SMAD3 and confirmed our
model’s prediction that many SMAD3 target genes are downregu-
lated early in HD.
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regulatory networks
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Introduction
Massive changes in gene expression accompany many human
diseases, yet we still know relatively little about how specific tran-
scription factors (TFs) mediate these changes. Comprehensive char-
acterization of disease-related transcriptional regulatory networks
(TRNs) can help clarify potential disease mechanisms and prioritize
targets for novel therapeutics. A variety of approaches have been
developed to reconstruct interactions between TFs and their target
genes, including models focused on reconstructing the physical loca-
tions of transcription factor binding (Gerstein et al, 2012; Neph et al,
2012), as well as computational algorithms utilizing gene co-
expression to infer regulatory relationships (Friedman et al, 2000;
Bonneau et al, 2006; Margolin et al, 2006; Huynh-Thu et al, 2010;
Marbach et al, 2012; Reiss et al, 2015). These approaches have
yielded insights into the regulation of a range of biological systems,
yet accurate, genome-scale models of mammalian TRNs remain
elusive.
Several lines of evidence point to a specific role for transcrip-
tional regulatory changes in Huntington’s disease (HD). HD is a fatal
neurodegenerative disease caused by dominant inheritance of a
polyglutamine (polyQ)-coding expanded trinucleotide (CAG) repeat
in the HTT gene (MacDonald et al, 1993). Widespread transcrip-
tional changes have been detected in post-mortem brain tissue from
HD cases versus controls (Hodges et al, 2006), and transcriptional
changes are among the earliest detectable phenotypes in HD mouse
models (Luthi-Carter et al, 2000; Seredenina & Luthi-Carter, 2012;
preprint: Bragg et al, 2016; Langfelder et al, 2016; Ament et al,
2017). These transcriptional changes are particularly prominent in
the striatum, the most profoundly impacted brain region in HD
(Vonsattel et al, 1985; Tabrizi et al, 2013). Replicable gene expres-
sion changes in the striatum of HD patients and HD mouse models
include downregulation of genes related to synaptic function in
medium spiny neurons accompanied by upregulation of genes
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related to neuroinflammation (Seredenina & Luthi-Carter, 2012;
Labadorf et al, 2015).
Some of these transcriptional changes may be directly related to
the functions of the huntingtin (HTT) protein. Both wild-type and
mutant HTT (mHTT) protein have been shown to associate with
genomic DNA, and mHTT also interacts with histone-modifying
enzymes and is associated with changes in chromatin states (Benn
et al, 2008; Thomas et al, 2008; Seong et al, 2010). Wild-type HTT
protein has been shown to regulate the activity of some TFs
(Zuccato et al, 2007). Also, high concentrations of nuclear mHTT
aggregates sequester TF and co-factor proteins and interfere with
genomic target finding, though it is unknown whether this occurs at
physiological concentrations of mHTT (Wheeler et al, 2000;
Shirasaki et al, 2012; Li et al, 2016). Roles for several TFs in HD have
been characterized (Zuccato et al, 2003; Arlotta et al, 2008; Tang
et al, 2012; Dickey et al, 2015), but we lack a global model for the
relationships between HD-related changes in the activity of specific
TFs and the downstream pathological processes that they regulate.
The availability of large transcriptomics datasets related to HD is
now making it possible to begin comprehensive network analysis of
the disease, particularly in mouse models. Langfelder et al (2016)
generated RNA-seq from the striatum of 144 knock-in mice
heterozygous for an allelic series of HD mutations with differing
CAG repeat lengths, as well as 64 wild-type littermate controls. They
used gene co-expression networks to identify modules of co-
expressed genes with altered expression in HD. However, their anal-
yses did not attempt to identify any of the TFs responsible for these
gene expression changes.
Here, we investigated the roles of core TFs that are predicted to
drive the gene expression changes in HD, using a comprehensive
network biology approach. We used a machine learning strategy to
reconstruct a genome-scale model for TF-target gene interactions in
the mouse striatum, combining publicly available DNase-seq with
brain transcriptomics data from HD mouse models. We identified 48
core TFs whose predicted target genes were overrepresented among
differentially expressed genes in at least five of fifteen conditions
defined by a mouse’s age and CAG repeat length, and we replicated
the predicted core TFs and differential gene expression associations
in multiple datasets from HD mouse models and from HD cases and
controls. Based on the coordinated downregulation in HD knock-in
mice of transcripts and proteins for Smad3 and its predicted target
genes, we hypothesized that SMAD3 may be a core regulator of
early gene expression changes in HD. Using chromatin immunopre-
cipitation and deep sequencing (ChIP-seq), we demonstrate CAG
repeat-dependent changes in SMAD3 occupancy and downregula-
tion of SMAD3 target genes in mouse brain tissue. In conclusion,
the results from our TRN analysis and ChIP-seq studies of HD reveal
new insights into predicted transcription factor drivers of complex
gene expression changes in this neurodegenerative disease.
Results
A genome-scale transcriptional regulatory network model of the
mouse striatum
We reconstructed a model of TF-target gene interactions in the
mouse striatum by integrating information about transcription factor
binding sites (TFBSs) with evidence from gene co-expression in the
mouse striatum (Fig 1A). We predicted the binding sites for 871 TFs
in the mouse genome using digital genomic footprinting. We identi-
fied footprints in DNase-seq data from 23 mouse tissues (Yue et al,
2014) using Wellington (Piper et al, 2013). Footprints are defined as
short genomic regions with reduced accessibility to the DNase-I
enzyme in at least one tissue. Our goal in combining DNase-seq data
from multiple tissues was to reconstruct a single TFBS model that
could make useful predictions about TF-target genes, even in condi-
tions for which DNase-seq data were not available. We identified
3,242,454 DNase-I footprints. Genomic footprints are often indica-
tive of occupancy by a DNA-binding protein. We scanned these foot-
prints for 2,547 sequence motifs from TRANSFAC (Matys et al,
2006), JASPAR (Mathelier et al, 2014), UniProbe (Hume et al,
2015), and high-throughput SELEX (Jolma et al, 2013) to predict
binding sites for specific TFs (TFBSs), and we compared these
TFBSs to the locations of transcription start sites. We considered a
TF to be a potential regulator of a gene if it had at least one binding
site within a 5-kb region upstream and downstream of the TSS,
which had been shown previously to maximize target gene predic-
tion from digital genomic footprinting of the human genome
(Plaisier et al, 2016).
To assess the accuracy of this TFBS model, we compared our TFBS
predictions to ChIP-seq experiments from ENCODE (Yue et al, 2014)
and ChEA (Lachmann et al, 2010; Appendix Fig S1). For 50 of 52 TFs,
there was significant overlap between the sets of target genes
predicted by our TFBS model versus ChIP-seq (FDR < 1%). Our TFBS
model had a median 78% recall of target genes identified by ChIP-seq
and a median 22% precision. That is, our model identified the major-
ity of true-positive target genes but also made a large number of false-
positive predictions. Low precision is expected in this model, since
TFs typically occupy only a subset of their binding sites in a given
tissue. Nonetheless, low precision indicates a need for additional filter-
ing steps to identify target genes that are relevant in a specific context.
We sought to identify TF-target gene interactions that are active
in the mouse striatum, by evaluating gene co-expression patterns in
RNA-seq transcriptome profiles from the striatum of 208 mice
(Langfelder et al, 2016). The general idea is that active regulation of
a target gene by a TF is likely to be associated with strong TF-gene
co-expression, and TFBSs allow us to identify direct regulatory inter-
actions. This step also removes TFs with low expression: Of the 871
TFs with TFBS predictions, we retained as potential regulators the
718 TFs that were expressed in the striatum. We fit a regression
model to predict the expression of each gene based on the combined
expression patterns of TFs with one or more TFBSs 5 kb of that
gene’s transcription start site. We used LASSO regularization to
select the subset of TFs whose expression patterns together predicted
the expression of the target gene. This approach extends several
previous regression methods for TRN reconstruction (Tibshirani,
1996; Bonneau et al, 2006; Friedman et al, 2010; Chandrasekaran
et al, 2011; Haury et al, 2012) by introducing TFBS-based
constraints. In preliminary work, we considered a range of LASSO
and elastic net (a = 0.2, 0.4, 0.6, 0.8, 1.0) regularization penalties
and evaluated performance in fivefold cross-validation (see Materials
and Methods). We selected LASSO based on the highest correlation
between prediction accuracy in training versus test sets.
We validated the predictive accuracy of our TRN model by
comparing predicted versus observed expression levels of each
2 of 16 Molecular Systems Biology 14: e7435 | 2018 ª 2018 The Authors
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gene. Our model explained > 50% of expression variation for
13,009 genes in training data (Fig 1B). Prediction accuracy in five-
fold cross-validation was nearly identical to prediction accuracy in
training data. That is, genes whose expression was accurately
predicted in the training data were also accurately predicted in the
test sets (r = 0.94; Fig 1B). Genes whose expression was not accu-
rately predicted generally had low expression in the striatum
(Appendix Fig S2). We removed poorly predicted genes, based on
their training set accuracy before moving to the test set. The final
TRN model contains 13,009 target genes regulated by 718 TFs via
176,518 interactions (Dataset EV1). Our model predicts a median of
14 TFs regulating each target gene and a median of 147 target genes
per TF (Fig 1C and D). Fifteen TFs were predicted to regulate
> 1,000 target genes (Appendix Fig S3). Importantly, TF-target gene
interactions retained in our striatum-specific TRN model were
enriched for genomic footprints in whole brains of 8-week-old
A
B
C E
D
Figure 1. Reconstruction and validation of a transcriptional regulatory network (TRN) model of the mouse striatum.
A Schematic for reconstruction of tissue-specific TRN models by combining information about TF binding sites with evidence from co-expression.
B Training (black) and test set (blue) prediction accuracy for genes in the mouse striatum TRN model. Genes are ordered on the x-axis according to their training set
prediction accuracy (r2, predicted versus actual expression). The dotted black line indicates the cut off for the number of genes which the model explained > 50% of
expression variation in training data.
C Distribution for the number of predicted regulators per target gene.
D Distribution for the number of predicted target genes per TF.
E Enrichments of TF-target gene interactions in the mouse striatum TRN for TFBSs supported by DNase footprints identified in 23 tissues.
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C57BL/6 male mice (P = 1.4e-82) and in fetal brain (P = 2.1e-88),
supporting the idea that these TF-target gene interactions reflect TF
binding sites in the brain (Fig 1E).
We defined “TF-target gene modules” as the sets of genes
predicted to be direct targets of each of the 718 TFs. Of these 718
TF-target gene modules, 135 were enriched for a functional category
from Gene Ontology (Ashburner et al, 2000; FDR < 5%, adjusting
for 4,624 GO terms). Of the 718 TF modules, 337 were enriched
(P < 0.01) for genes expressed specifically in a major neuronal or
non-neuronal striatal cell type (Doyle et al, 2008; Dougherty et al,
2010; Zhang et al, 2014), including known cell-type-specific activi-
ties for both neuronal (e.g., Npas1-3) and glia-specific TFs (e.g.,
Olig1, Olig2) (Appendix Fig S4). These results suggest that many
TRN modules reflect the activities of TFs on biological processes
within specific cell types.
Prediction of core TFs associated with transcriptional changes in
HD mouse models
We next sought to identify TFs that are core regulators of transcrip-
tional changes in HD. Of the 208 mice in the RNA-seq dataset used
for network reconstruction, 144 were heterozygous for a human
HTT exon 1 allele knocked into the endogenous Htt locus (Wheeler
et al, 1999; Menalled et al, 2003; Langfelder et al, 2016), and the
remaining 64 mice were C57BL/6J littermate controls. Six distinct
Htt alleles differing in the length of the CAG repeat were used. In
humans, the shortest of these alleles—HttQ20—is non-pathogenic,
and the remaining alleles—HttQ80, HttQ92, HttQ111, HttQ140, and
HttQ175—are associated with progressively earlier onset of pheno-
types. We used RNA-seq data generated by Langfelder et al
(Langfelder et al, 2016) from four male and four female mice of
each genotype at each of three time points: 2-month-old, 6-month-
old, and 10-month-old mice. These mouse models undergo subtle
age- and allele-dependent changes in behavior, and all of the ages
profiled precede detectable neuronal cell death (Carty et al, 2015;
Rothe et al, 2015; Alexandrov et al, 2016; preprint: Bragg et al,
2016).
We evaluated gene expression differences between HttQ20/+ mice
and mice with each of the five pathogenic Htt alleles at each time
point, a total of 15 comparisons. The extent of gene expression
changes increased in an age- and CAG length-dependent fashion,
with extensive overlap between the DEGs identified in each condi-
tion (Fig 2). A total of 8,985 genes showed some evidence of dif-
ferential expression (DEGs; P < 0.01) in at least one of the 15
conditions, of which 5,132 were significant at a stringent false
discovery rate < 1%. These results suggest that robust and replica-
ble gene expression changes occur in the striatum of these HD
mouse models at ages well before the onset of neuronal cell death
or other overt pathology.
The predicted target genes of 209 TFs were overrepresented for
DEGs in at least one of the 15 conditions (three ages × five mouse
models; Fisher’s exact test, P < 1e-6; Dataset EV2). Repeating this
analysis in 1,000 permuted datasets indicated that enrichments at
this level of significance never occurred in more than four condi-
tions (i.e., zero instances in 718,000 tests across 1,000 permutations
of 718 TF-target gene networks). We therefore focused on a core set
of 48 TFs whose predicted target genes were overrepresented for
DEGs in five or more conditions. Notably, 44 of these 48 TFs were
differentially expressed (FDR < 0.01) in at least one of the 15 condi-
tions (Appendix Fig S5). We refer to these 48 TFs as core TFs.
Replication of core TFs in independent datasets
We sought to replicate the associations of core TFs in HD by testing
for enrichment of TF-target gene modules for differentially
expressed genes or proteins in independent HD-related datasets.
First, we conducted a meta-analysis of differentially expressed TF-
target gene modules in four independent microarray gene expres-
sion profiling studies of striatal tissue from HD mouse models (Kuhn
et al, 2007; Becanovic et al, 2010; Fossale et al, 2011; Giles et al,
2012). Targets of 46 of the 48 core TFs were enriched for DEGs
(meta-analysis P-value < 0.01; Fig 3A and B) in the microarray data.
The overlap between TFs whose target genes were differentially
expressed in HD versus control mice in microarray datasets and the
core TFs from our primary dataset was significantly greater than
expected by chance (Fisher’s exact test: P = 5.7e-32). These results
suggest that transcriptional changes in most of the core TF-target
gene modules were preserved across multiple datasets and mouse
models of HD.
Next, we asked whether the target genes of core TFs were also
differentially abundant at the protein level. We studied quantitative
proteomics data from the striatum of 64 6-month-old HD knock-in
mice (Langfelder et al, 2016). These were a subset of the mice pro-
filed with RNA-seq in our primary dataset. Targets of 22 of the 48
core TFs were enriched for differentially abundant proteins (Fisher’s
exact test, P < 0.01; Fig 3A and B). The overlap between TFs whose
target genes were differentially abundant between CAG-expanded
versus wild-type mice and the core regulator TFs was significantly
greater than expected by chance (Fisher’s exact test: P = 5.7e-20).
Third, we asked whether TFs predicted to drive early gene
expression changes in mouse models of HD might also regulate gene
expression changes in human disease. This analysis is complicated
2 months 6 months 10 months
0
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00
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00
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s
Figure 2. Robust changes in striatal gene expression in 2-, 6-, and 10-
month-old HD knock-in mice.
Counts of differentially expressed genes in eachmousemodel at each time point
(allele shown versus Q20; edgeR log ratio test; nominal P-value < 0.01).
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Figure 3. Replication of core TFs in independent datasets.
A Venn diagram showing overlap between core regulator TF-target gene modules identified in the primary RNA-seq dataset, compared to TF-target gene modules
enriched for differentially expressed genes in three independent datasets.
B log10(P-values) for the strength of enrichment of each of the core regulator TF-target gene modules for differentially expressed genes in each of the four datasets.
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by the fact that striatal samples available from post-mortem HD
patients are almost universally from late-stage disease, whereas our
studies in mice focus on much earlier time points. In addition, the
striatum is heavily degraded in late-stage HD, with many dead
neurons and extensive astrogliosis (Vonsattel et al, 1985). For these
reasons, transcriptomic changes in HD cases versus controls that
are closely related to pathogenesis may be masked by a multitude of
transcriptomic changes that are secondary to pathology. To over-
come these issues and maximize our ability to detect overlap with
the mouse models, we performed two tests in which we considered
either a restrictive set of TFs from the HD mouse models (the 48
core regulators), as well as a broader set of TFs (all 209 TFs whose
predicted target genes were enriched in at least one condition from
our primary mouse RNA-seq dataset). We reconstructed a TRN
model specific to the human striatum by integrating a map of TFBSs
(Plaisier et al, 2016) based on digital genomic footprinting of 41
human cell types (Neph et al, 2012) with microarray gene expres-
sion profiles of post-mortem striatal tissue from 36 HD cases and 30
controls (Hodges et al, 2006). As in our TRN model for the mouse
striatum, we fit a LASSO regression model to predict the expression
of each gene in human striatum from the expression levels of TFs
with predicted TFBSs within 5 kb of its transcription start sites
(Appendix Fig S6). A total of 616 TFs had one-to-one orthology and
≥ 10 predicted target genes in both the mouse and human striatum
TRN models. Using these 616 human TF-target gene modules, we
tested the enrichment of differentially expressed genes in the
caudate nucleus (part of the dorsal striatum) from HD cases versus
controls (Hodges et al, 2006; Durrenberger et al, 2015). Predicted
target genes for 13 of the 48 core TFs from mouse striatum were also
overrepresented among differentially expressed genes in HD cases
versus controls. This overlap was not statistically greater than
expected by chance (odds ratio = 1.79; P = 0.05; Fig 3A and B).
However, when we considered the broader set of 209 TF-target gene
modules from the primary mouse RNA-seq dataset, we found signif-
icant overlap for TF-target gene modules that were downregulated
both in HD and in HD mouse models (28 shared TF-target gene
modules; odds ratio = 3.6, P = 5.0e-5; Appendix Fig S6D) and for
TF-target gene modules that were upregulated both in HD and in
HD mouse models (26 shared TF-target gene modules; odds
ratio = 1.8, P = 0.02; Appendix Fig S6E). These results suggest that
some transcriptional programs are shared between the earliest
stages of molecular progression (assayed in mouse models) and late
stages of human disease. However, the human data support for rela-
tively few of the core 48 TFs from mouse models.
Fourth, we asked whether core TFs in striatum also regulate HTT
CAG length-dependent gene expression changes in other tissues. We
analyzed gene expression in the cortex, hippocampus, cerebellum,
and liver of HTT knock-in mice, using RNA-seq of these tissues from
168 of the mice in our primary striatal dataset (Langfelder et al,
2016). For each tissue, we reconstructed a transcriptional regulatory
network model equivalent to our TRN model for mouse striatum,
and we tested for the enrichment of Htt-allele-dependent gene
expression changes among the predicted targets of each TF (Dataset
EV3). We found a statistically significant overlap between the 48
core TFs in striatum versus the TF-target gene modules enriched for
differentially expressed genes in each of the other four tissues (48
core TFs in striatum versus enriched modules in cortex: 16 shared
TFs, odds ratio = 2.6, P = 3.4e-3; striatum versus hippocampus: 21
shared TFs, odds ratio = 3.0, P = 4.1e-4; striatum versus cerebel-
lum: 17 shared TFs, odds ratio = 2.17, P = 1.3e-2; striatum versus
liver: 25 shared TFs, odds ratio = 3.3, P = 8.2e-5). These analyses
revealed a wide range of tissue specificity for the associations of the
48 core striatal TFs with HTT CAG length-dependent gene expres-
sion changes (Appendix Fig S7). For instance, the predicted targets
of RXRG were enriched for differentially expressed genes in all five
tissues, whereas targets of IRF2 were enriched only in striatum.
Notably, targets of 13 of the 48 core regulator TFs were enriched
for differentially expressed genes in all four striatal datasets: GLI3,
IRF2, KLF16, NPAS2, PAX6, RARB, RFX2, RXRG, SMAD3, TCF12,
TEF, UBP1, and VEZF1. These 13 TFs may be especially interesting
for follow-up studies.
Biological associations of core TFs
We evaluated relationships among the 48 core TFs based on cluster-
ing and network topology. Plotting TF-to-TF regulatory interactions
among the 48 core TFs (Fig 4A–D) revealed two distinct TF-to-TF
sub-networks, characterized by numerous positive interactions
within sub-networks and by fewer, mostly inhibitory interactions
between sub-networks. The target genes of TFs in the first sub-
network were predominantly downregulated in HD, while the target
genes of TFs in the second sub-network were predominantly upreg-
ulated. Hierarchical clustering of the 48 core TFs based on the
expression patterns of their predicted target genes revealed similar
groupings of TFs whose target genes were predominantly down-
versus upregulated (Fig 5).
We studied the predicted target genes of each core TF to charac-
terize possible roles for these TFs in HD. Downregulated TF-target
gene modules were overrepresented for genes specifically expressed
in DRD1+ and DRD2+ medium spiny neurons (Fig 5). Functional
enrichments within these modules were mostly related to synaptic
function, including metal ion transmembrane transporters (targets
of NPAS2, P = 2.3e-4), voltage-gated ion channels (targets of MAFA,
P = 8.1e-4), and protein localization to cell surface (targets of RXRG,
P = 1.7e-4). These network changes may be linked to synapse loss
in medium spiny neurons, which is known to occur in knock-in
mouse models of HD (Deng et al, 2013).
Some upregulated TF-target gene modules were overrepresented
for genes specifically expressed in oligodendrocytes or astrocytes,
while others were overrepresented for genes specifically expressed
in neurons (Fig 5). Functional enrichments within these modules
included Gene Ontology terms related to apoptosis (“positive regula-
tion of extrinsic apoptotic signaling pathway via death domain
receptors,” targets of WT1, P = 1.8e-4) and DNA repair (targets of
RUNX2, “single-strand selective uracil DNA N-glycosylase activity,”
P = 2.0e-4). Therefore, core TFs whose target genes were predomi-
nantly upregulated may contribute to a variety of pathological
processes both in neurons and in glia. Oligodendrocyte counts have
been shown to be increased in HD mutation carriers, whereas
micro- and astrogliosis are thought to begin later in disease progres-
sion (Vonsattel et al, 1985).
An open question in the field is whether the same sequence of
pathogenic events underlies disease progression in juvenile-onset
HD due to HTT alleles with CAG tracts with > 60 repeats versus
adult-onset HD due to HTT alleles with  40–60 CAG repeats
(Nance & Myers, 2001). This question is of practical relevance for
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modeling HD in mice, since mouse models with very long CAG
tracts are often used in research due to their faster rates of pheno-
typic progression within a 2-year lifespan. To address this question,
we evaluated overlap between TF-target gene modules activated at
the earliest time points in mice with each of the five pathogenic Htt
alleles in our dataset. In the mice with the longest Htt alleles—
HttQ175 and HttQ140—the target genes of core TFs first became
enriched for differentially expressed genes in 2-month-old mice. In
mice with relatively short Htt alleles—HttQ111, HttQ92, and HttQ80—
target genes of core TFs became enriched for differentially expressed
genes beginning in 6-month-old mice. We found that eight modules—
the predicted target genes of IRF2, MAFA, KLF16, LMO2, NPAS2,
RUNX2, RXRG, and VEZF1—were significantly enriched for DEGs in at
least three of these five conditions (2-month-old HttQ175/+, 2-month-
old HttQ140/+, 6-month-old HttQ111/+, 6-month-old HttQ92/+, and 6-
month-old HttQ80/+). A limitation of this analysis is that the alleles
used in this study are associated with juvenile-onset disease, and the
extent to which these results extend to adult-onset alleles remains to
be determined. Nonetheless, these results suggest that many aspects of
the trajectory of transcriptional changes are shared across the CAG
lengths that have been studied. Notably, all the TFs whose target genes
were enriched for differentially expressed genes at the very earliest
time points were enriched primarily for genes that were downregulated
in HD. Strong enrichments of TF-target gene modules for upregulated
genes occurred only at slightly later time points.
Genome-wide characterization of SMAD3 binding sites in the
mouse striatum supports a role in early gene dysregulation in HD
We selected the TF SMAD3 for functional validation for the follow-
ing reasons. SMAD3 was one of 13 core TFs whose predicted target
genes were overrepresented among differentially expressed genes
across all four independent datasets. SMAD3’s predicted target
genes were predominantly downregulated in an age- and CAG
length-dependent fashion, beginning at or before 6 months of age
(Fig 5). SMAD3 acts primarily downstream of TGF-b signaling,
making it a potential drug target. In addition, an initial screen of
antibodies to several of the core TFs revealed a high-quality SMAD3
antibody, suitable for chromatin immunoprecipitation.
Decreased expression of SMAD3 target genes could result from a
change in SMAD3 expression. In addition, changes in the expression
levels of SMAD3 target genes could result from a change in TGF-b
signaling, as SMAD3 activation and nuclear localization depend on
its phosphorylation at Ser423 and Ser425 by the TGF-b receptor (Liu
et al, 1997). To evaluate these possibilities, we examined Smad3
RNA, phospho-Ser423/425-SMAD3 protein, and total SMAD3
protein in the striatum of HD knock-in mice versus wild-type
controls. We detected an age- and CAG length-dependent decrease
in Smad3 RNA, similar to the expression of its predicted target genes
(Fig 6A). In addition, Western blots revealed a trend toward a lower
ratio of phospho-Ser423/425-SMAD3 to total SMAD3 in the striatum
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Figure 4. Predicted TF-to-TF interactions among 48 putative core regulators of transcriptional changes in mouse models of Huntington’s disease.
A–D Nodes and edges indicate direct regulatory interactions between TFs predicted by the mouse striatum TRN model. Solid black arrows and dotted red arrows
indicate positive versus inhibitory regulation, respectively, and the width of the line is proportional to the predicted effect size. Blue and orange shading of nodes
indicates that the TF’s target genes are overrepresented for downregulated versus upregulated genes in HD mouse models, respectively. If a TF’s target genes are
enriched in both directions, the stronger enrichment is shown. Each panel indicates the network state in a specific condition: (A) 2-month-old HttQ92/+ mice, (B) 6-
month-old HttQ92/+ mice, (C) 2-month-old HttQ175/+ mice, or (D) 6-month-old HttQ175/+ mice.
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of 4- and 11-month-old HttQ111/+ mice, compared to wild-type
controls (ANOVA, genotype: F1,16 = 3.714, P = 0.072; age: F1,16 =
4.590, P = 0.048; interaction: F1,16 = 0.304, P = 0.589), suggesting a
possible decrease in the activation by TGF-b (Appendix Fig S8). By
contrast, we did not detect a significant change in total SMAD3
protein in these mice (ANOVA, genotype: F1,16 = 0.487, P = 0.495;
age: F1,16 = 0.506, P = 0.487; interaction: F1,16 = 1.085, P = 0.313;
Appendix Fig S8). Similarly, quantitative proteomics of an allelic
series of 6-month-old HD knock-in mice revealed a non-significant
trend toward decreased total SMAD3 protein (Pearson’s correlation;
SMAD3 versus Htt CAG length: r = 0.25, P-value = 0.12). In
summary, we find evidence for decreased Smad3 RNA expression
and a trend toward decreased SMAD3 activation by TGF-b in the
striatum of HD knock-in mice, though any changes in SMAD3
protein are subtle. Overall, these results support our prediction from
network modeling that decreased SMAD3 activity is an early event
in the striatum of Htt CAG knock-in mice.
Next, we characterized the binding sites of SMAD3 in the stria-
tum of 4-month-old HttQ111/+ mice and wild-type littermate controls
to validate and extend our network predictions. We performed
Figure 5. Enrichments of the 48 core TFs for differentially expressed genes in each condition and for cell-type-specific genes.
Heatmap showing the enrichments of each TF’s target genes for down- and upregulated genes for each Htt allele at each time point as well as enrichments of each TF’s target
genes for genes expressed specifically in one of sevenmajor cell types in themouse striatum. Arrows at top indicate the 13 TFswith replication in all four independent datasets.
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chromatin immunoprecipitation and deep sequencing using an anti-
body specific to SMAD3 (ChIP-seq; n = 2 pooled samples per group,
with each pool containing DNA from three mice). Peak-calling
revealed 57,772 SMAD3 peaks (MACS2.1, FDR < 0.01 and > 10
reads in at least two of the four samples). Of the 57,772 SMAD3
peaks, 34,633 (59.9%) were located within 10 kb of transcription
start sites (TSSs), including at least one peak within 10 kb of the
TSSs for 11,727 genes (Fig 6B). The summits of SMAD3 peaks were
enriched for the SMAD2:SMAD3:SMAD4 motif (P-value = 7.2e-85;
Fig 6C). Importantly, the TSSs for 753 of the 938 computationally
predicted SMAD3 target genes in our TRN model were located
within 10 kb of at least one ChIP-based SMAD3 binding site. This
overlap was significantly greater than expected by chance (odds
ratio = 4.33, P-value = 2.8e-84).
We characterized the relationship between SMAD3 occupancy
and transcriptional activation by measuring the genomic occupancy
of RNA polymerase II (RNAPII) in the striatum of HttQ111/+ and
wild-type mice. RNAPII occupancy is a marker of active transcrip-
tion and of active transcription start sites. Occupancy of SMAD3 and
occupancy of RNAPII were positively correlated, across all genomic
regions (r = 0.70) and specifically within SMAD3 peaks (r = 0.71).
Thus, SMAD3 binding is associated with active transcription.
Similarly, we characterized the relationship between SMAD3
occupancy and chromatin accessibility, using publicly available
DNase-seq of midbrain tissue from wild-type mice. Of the 57,772
SMAD3 peaks, 22,650 (39.2%) overlapped a DNase-hypersensitive
site in the midbrain. Occupancy of SMAD3 was positively correlated
with DNase-I hypersensitivity across all genomic regions (r = 0.33)
and specifically within SMAD3 peaks (r = 0.25). Thus, SMAD3 bind-
ing sites are enriched for signatures of active enhancers.
We ranked genes from highest to lowest SMAD3 regulatory
potential based on the number of SMAD3 peaks within 10 kb of
their transcriptional start sites. We focused on the top 837 genes
with SMAD3 peak counts > 2 standard deviations above the mean.
These top 837 SMAD3 target genes were enriched (FDR < 0.01)
for 24 non-overlapping clusters of Gene Ontology terms
(Appendix Table S1). These enriched GO terms prominently
featured pathways related to gene regulation (“mRNA processing”,
P = 4.2e-9; “histone modification”, P = 1.7e-7; “transcriptional
repressor complex”, P = 3.7e-5), as well as functions more specifi-
cally related to brain function (“neuromuscular process controlling
balance”, P = 1.2e-7; “brain development”, P = 1.27e-6; “neuronal
cell body”, P = 2.5e-5).
We performed quantitative and qualitative analyses to compare
SMAD3 occupancy in HttQ111/+ versus wild-type mice. Of the
57,772 SMAD3 peaks, 51,721 (89.5%) were identified in both
HttQ111/+ and wild-type mice. A total of 5,419 peaks (9.4%) were
identified only in wild-type mice, while only 632 peaks (1.1%) were
identified only in HttQ111/+ mice (Fig 6D). Quantitative analyses of
differential binding with edgeR revealed four peaks whose occu-
pancy was significantly different (FDR < 0.05) between HttQ111/+
and wild-type mice. All four of these peaks were more weakly occu-
pied in HttQ111/+ mice. A total of 138 peaks had nominally signifi-
cant differences in occupancy between genotypes (P < 0.01). Of
these 138 peaks, 133 (96.4%) were more weakly occupied in
HttQ111/+ mice (Fig 6E). These results suggest that SMAD3 occu-
pancy is decreased at a subset of its binding sites in 4-month-old
HttQ111/+ mice.
Finally, we tested whether the top 837 SMAD3 target genes from
ChIP-seq were differentially expressed in HD knock-in mice. The top
837 SMAD3 target genes from ChIP-seq were significantly overrepre-
sented among genes that became downregulated in the striatum of
HD knock-in mice (223 downregulated SMAD3 target genes; odds
ratio = 2.0, P-value = 3.4e-15; Fig 6F). Example target gene tracks
are shown in Fig 6G–I including differentially expressed genes
Adcy5, Kcnt1, and Pde1b. By contrast, SMAD3 target genes were not
overrepresented among genes that became upregulated in the stria-
tum of HD mouse models (143 upregulated SMAD3 target genes,
odds ratio = 0.92, P = 0.40). These results are consistent with our
computational model, in which SMAD3 target genes were primarily
downregulated in HD knock-in mice. Therefore, reduced SMAD3
binding is associated with downregulation of its target genes in HD
mouse models.
Discussion
Here, we identified putative core TFs regulating gene expression
changes in HD by reconstructing genome-scale transcriptional regu-
latory network models for the mouse and human striatum. Identify-
ing core TFs in HD provides insights into the mechanisms of this
devastating, incurable disease. This method to reconstruct models
of mammalian transcriptional regulatory networks can be readily
applied to find regulators underlying any trait of interest.
Our model extends prior knowledge about the TFs involved in
HD. A role in HD for RARB is supported by ChIP-seq and transcrip-
tome profiling of striatal tissue from Rarb/ mice (Niewiadomska-
Cimicka et al, 2016). A role in HD for FOXO1 is supported by experi-
mental evidence that FOXO signaling influences the vulnerability of
striatal neurons to mutant huntingtin (Parker et al, 2012). A role in
HD for RELB is supported by experimental evidence that NF-jB
signaling mediates aberrant neuroinflammatory responses in HD
and HD mouse models (Hsiao et al, 2013). Notably, microglia
counts in 10–12 months HttQ111/+ mice indicate that these cells are
◀ Figure 6. SMAD3 expression, genomic occupancy, and target gene expression in the striatum of HD mouse models.A Progressive age- and Htt-allele-dependent changes in the expression of SMAD3 in mouse striatum. Bars indicate z-scores for the expression level in heterozygous
mice with each pathogenic Htt allele compared to age-matched HttQ20/+ mice.
B Distribution of the distances of 57,772 SMAD3 peaks identified by ChIP-seq to the nearest transcription start site (TSS).
C The summits of SMAD3 peaks are enriched for the sequence motif recognized by SMAD3 (JASPAR CORE MA0513.1, shown in inset).
D Overlap between peaks identified in HttQ111/+ versus wild-type mice.
E SMAD3 occupancy is decreased at a subset of peaks in HttQ111/+ versus wild-type mice. x-axis and y-axis represent the log2(fold change) and log10(P-value),
respectively, for each peak region.
F Age- and Htt-allele-dependent expression patterns of the top 50 most strongly differentially expressed SMAD3 target genes.
G–I Genomic occupancy of SMAD3 and RNA polymerase II and accessibility of genomic DNA to DNase-I near (G) Adcy5, (H) Kcnt1, and (I) Pde1b.
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not proliferating (preprint: Bragg et al, 2016), suggesting that the
transcriptional changes observed in our study represent a proin-
flammatory state, rather than microgliosis per se. Other predicted
core TFs, including KLF16 and RXRG, have previously been noted
among differentially expressed genes in mouse models of HD
(Seredenina & Luthi-Carter, 2012). In some cases, known functions
for core TFs suggest hypotheses about their roles in HD. For
instance, NPAS2 is a component of the molecular clock, so its
dysfunction could contribute to circadian disturbances in HD
(Morton et al, 2005). Notably, the predicted target genes for several
TFs whose functions in HD have been studied by other investigators
—for example, REST (Zuccato et al, 2003), SREBF2 (Valenza et al,
2005), and FOXP1 (Tang et al, 2012)—were overrepresented for
differentially expressed genes in our model, but only at later time
points or more weakly than our top 48 core regulator TFs.
Our results suggest that HD involves parallel, asynchronous
changes in distinct down- versus upregulated TF sub-networks.
Targets of TFs in the downregulated sub-network are enriched for
synaptic genes and appear to be primarily neuronal. Targets of TFs in
the upregulated sub-network are enriched for stress response path-
ways (e.g., DNA damage repair, apoptosis). These upregulated
networks appear to involve processes occurring in both neurons and
glia. Downregulation of synaptic gene networks preceded upregula-
tion of stress response gene networks, suggesting that the synaptic
changes are more proximal to the mutant HTT protein. A large body
of prior work provides independent support for synaptic changes in
medium spiny neurons and of activated gliosis in HD pathogenesis
(Singhrao et al, 1999; Deng et al, 2013; Hsiao et al, 2013).
Replication across four independent datasets revealed 13 TFs
whose target genes were most consistently enriched among differen-
tially expressed genes. We propose that these TFs should be prioritized
for follow-up experiments, both to validate predicted target genes and
to evaluate specific biological functions for each TF. For instance, it
will be interesting to determine which (if any) of the core TFs have
direct protein–protein interactions with the HTT protein and to test
our model’s predictions about TF perturbations with specific aspects
of HD pathology. The target genes for most of these 13 TFs were
enriched for genes that were downregulated in HD and for neuron-
specific genes, consistent with the idea that pathological changes origi-
nate in medium spiny neurons. It is important to note that indepen-
dent datasets comprised from different mouse models, ages, and data
collection centers might dilute the reproducibility of key comparisons.
We feel that our analysis approach—comparing across multiple inde-
pendent studies—is therefore more stringent and retains only those
predictions for which there is consistent reproducibility.
Network modeling of SMAD3 target genes, changes in SMAD3
expression and phosphorylation, and SMAD3 ChIP-seq suggest that
SMAD3 and its target genes are downregulated in the striatum of
HD knock-in mice. Previous studies have described changes in
SMADs and upstream components of the TGF-b signaling pathway
in cellular and mouse models of HD, as well as in blood from HD
cases versus controls, but the direction of these effects was contra-
dictory between studies (Battaglia et al, 2011; Ring et al, 2015;
Bowles et al, 2017). Our results are the first characterization of this
system in the striatum of a genetically accurate mouse model with
physiological expression of mutant HTT and provide the first
evidence linking TGF-b and SMAD3 to downstream transcriptomic
changes in HD mouse models. These findings suggest an intriguing
possibility that agonists of TGF-b signaling could have therapeutic
benefit in HD patients. Consistent with this possibility, TGF-b treat-
ment reduced apoptotic cell death in neural stem cells with
expanded HTT CAG tracts (Ring et al, 2015).
Our method to reconstruct TRNs by integrating information
about TF occupancy with gene co-expression is likely to be broadly
applicable, providing a strategy to optimize both mechanistic and
quantitative accuracy. TRN reconstruction methods are based
purely on gene co-expression struggle to distinguish direct versus
indirect interactions. Physical models of TF occupancy provide poor
quantitative predictions because many TF binding sites are non-
functional or do not regulate the nearest gene. Our study demon-
strates that integrated TRN modeling can be utilized effectively to
study neurodegenerative diseases such as HD, combining data from
the ENCODE project with disease-specific transcriptome profiling.
Materials and Methods
Referenced datasets
We obtained RNA-seq and microarray gene expression profiling
data from the following GEO Datasets (http://www.ncbi.nlm.
nih.gov/geo/): GSE65776 (Langfelder et al, 2016), GSE73508,
GSE18551 (Becanovic et al, 2010), GSE32417 (Giles et al, 2012),
GSE9038 (Fossale et al, 2011), GSE9857 (Kuhn et al, 2007),
GSE26927 (Durrenberger et al, 2015), and GSE3790 (Hodges et al,
2006). We obtained proteomics data from the PRIDE archive
(https://www.ebi.ac.uk/pride/archive/), accession PXD003442
(Langfelder et al, 2016). For RNA-seq data (GSE65776), we down-
loaded read counts and FPKM estimates, mapped to ENSEMBL gene
models. For Affymetrix microarrays (GSE18551, GSE32417,
GSE9038, GSE9857, GSE26927, and GSE3790), we downloaded raw
image files and used the affy package in R to perform within-sample
RMA normalization and between-sample quantile normalization.
For proteomics data, we downloaded MaxQuant protein quantities.
Genomic footprinting
DNase-I digestion of genomic DNA followed by deep sequencing
(DNase-seq) enables the identification of genomic footprints across
the complete genome. We predicted genome-wide transcription
factor binding sites (TFBSs) in the mouse and human genomes based
on instances of TF sequence motifs in digital genomic footprints
from the ENCODE project. Short regions of genomic DNA occupied
by DNA-binding proteins produce characteristic “footprints” with
altered sensitivity to the DNase-I enzyme. DNase-I digestion of
genomic DNA followed by deep sequencing (DNase-seq) enables the
identification of genomic footprints across the complete genome.
For the human TFBS model, we used a previously described
database (Plaisier et al, 2016) of footprints from DNase-seq of 41
cell types (Neph et al, 2012). For the mouse TFBS model, we down-
loaded digital genomic footprinting data (deep DNase-seq) for 23
mouse tissues and cell types (Yue et al, 2014) from the UCSC
ENCODE portal on October 29, 2013: ftp://hgdownload.cse.ucsc.ed
u/goldenPath/mm9/database/. We detected footprints in each
sample with Wellington (Piper et al, 2013), using a significance
threshold, P < 1e-10. Using FIMO (Grant et al, 2011), we scanned
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the mouse genome (mm9) for instances of 2,547 motifs from
TRANSFAC (Matys et al, 2006), JASPAR (Mathelier et al, 2014),
UniPROBE (Hume et al, 2015), and high-throughput SELEX (Jolma
et al, 2013). We intersected footprints from all tissues with motif
instances to generate a genome-wide map of predicted TFBSs. A
motif can be recognized by multiple TFs with similar DNA-binding
domains. We assigned motifs to TF families using annotations from
the TFClass database (Wingender et al, 2013). In total, our model
included motifs recognized by 871 TFs.
Regression-based transcriptional regulatory network models
We fit a regression model to predict the expression of each gene in
mouse striatum, cortex, hippocampus, cerebellum, and liver, as well
as in human striatum, based on the expression patterns of TFs that
had predicted binding sites within 5 kb of that gene’s transcription
start sites. We applied LASSO regularization to penalize regression
coefficients and remove TFs with weak effects, using the glmnet
package in R. These methods were optimized across several large
transcriptomics datasets, prior to their application to the Hunting-
ton’s disease data. To reconstruct the TRN model for mouse stria-
tum, we used RNA-seq data from the striatum of 208 mice
(Langfelder et al, 2016). Prior to network reconstruction, we evalu-
ated within- and between-group variance and detected outlier
samples using hierarchical clustering and multidimensional scaling.
No major differences in variance were identified between groups,
and no outlier samples were detected or removed.
We considered a variety of model parameterization during the
initial model formulation. We considered elastic net regression and
ridge regression as alternatives to LASSO regression. We selected
LASSO based on the least falloff in performance from the training data
to test sets in fivefold cross-validation. We note that when multiple
TFs have correlated expression, the LASSO will generally retain only
one for the final model. This feature of the LASSO has been consid-
ered advantageous, since it can eliminate indirect interactions.
However, this feature also has a downside in that there is virtually no
doubt that the TFs selected by our model underestimate the true
number of TF-target gene interactions. We would only pick up domi-
nant effects where a linear model works reasonably well. Our primary
interest is ultimately in using this approach to find a relatively small
number of targets based on multiple lines of evidence. We are less
concerned here with finding everything than in trying to make sure
what we do find is as highly enriched for true positives as possible.
We also considered a variety of strategies to select an appropriate
penalty parameter. For instance, we could apply an independent
penalty parameter for each gene, or we could use a uniform penalty
parameter across all genes. We found that optimal performance was
obtained in both training data and fivefold cross-validation when
we applied a uniform penalty parameter across all genes. We
assigned this penalty parameter by evaluating performance in cross-
validation across a range of possible parameters for a random subset
of 100 genes. For each gene, we identified the most stringent penalty
such that the unfitted variance was < 1 standard error greater than
the minimum unfitted variance across all the penalty parameters
considered. We selected the median penalty defined by this proce-
dure across the 100 randomly selected gene.
Not all genes’ expression can be accurately predicted based on
the expression of TFs. To select genes for the final model, we
evaluated the variance explained by the model in a training set
consisting of 80% of the data. We selected those genes for which
the model explained > 50% of expression variance in the training
set and carried these genes forward to a test set, consisting of the
remaining 20% of genes. We found that training set performance
accurately predicted test performance (r = 0.94). We therefore fit a
final model for genes whose expression could be accurately
predicted in the training set. The result of these procedures is a
tissue-specific TRN model, predicting the TFs that regulate each
gene in the striatum and assigning a positive or negative weight for
each TF’s effect on that gene’s expression in the striatum.
Enrichments of TF-target gene modules in ChIP-seq data
We downloaded ChIP-seq data from the ENCODE website (encode-
project.org, accessed on August 20, 2015) for 33 mouse transcrip-
tion factors included in our TRN model. We identified genes whose
transcription start sites were located within 5 kb of a narrowPeak in
each ChIP experiment. We also downloaded a table of ChIP-to-gene
annotations for 19 additional mouse TFs from the ChEA website
(http://amp.pharm.mssm.edu/lib/chea.jsp, accessed on August 6,
2015). We tested for enrichments of the target genes identified by
ChIP for each of these 52 TFs to predicted TFBSs from our model.
Enrichments of TF-target gene modules for gene ontology terms
We downloaded Gene Ontology (GO) annotations for mouse genes
from GO.db on November 4, 2015, using the topGO R package. We
extracted the genes annotated to each GO term and its children, and
we used Fisher’s exact tests to characterize enrichments of TF-target
gene modules for the 4,624 GO terms that contain between 10 and
500 genes.
Enrichments of TF-target gene modules for cell-type-
specific genes
We characterized sets of genes expressed in each striatal cell type
using gene expression profiles from purified cell types (Doyle et al,
2008; Zhang et al, 2014) and the pAppendix R package for cell-type-
specific expression analysis (Dougherty et al, 2010). We used
Fisher’s exact tests to characterize enrichments of TF-target gene
modules for genes expressed specifically in each cell type.
Enrichments of TF-target gene modules for differentially
expressed genes
We identified genes that were differentially expressed in HD versus
control samples. In the primary dataset, we compared mice with the
non-pathogenic Q20 allele and mice with each of the other five alle-
les, separately for 2-, 6-, and 10-month-old mice. We used the edgeR
R package to fit generalized linear models and test for significance
of each contrast. We used Fisher’s exact tests to characterize enrich-
ments of downregulated genes and upregulated genes in each condi-
tion (significance threshold for differentially expressed genes,
P < 0.01) for the target genes of each TF. We considered enrich-
ments to be statistically significant at a raw P-value threshold < 1e-
6, or an adjusted P-value < 0.02 after accounting for 19,170 tests
(639 TFs × 5 Htt alleles × 3 time points × 2 tests/condition).
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To identify top TFs, accounting for non-independence among
genes and conditions, we calculated an empirical false discovery
rate for these enrichments. We repeated the edgeR and enrichment
analyses 1,000 times with permuted sample labels. We found that
no module had a P-value < 1e-6 in more than four conditions in any
of the permuted datasets. Therefore, we focused on TFs whose
target genes were overrepresented for differentially expressed genes
in five or more conditions.
We performed similar analyses to characterize TF-target gene
modules enriched for genes that were differentially expressed in
replication samples. We used the limma R package to calculate dif-
ferentially expressed genes in each of the four microarray studies
from mouse striatum (Kuhn et al, 2007; Becanovic et al, 2010;
Fossale et al, 2011; Giles et al, 2012). We calculated enrichments of
the DEGs from each study for TF-target gene modules. We then
combined the enrichment P-values across the four studies using
Fisher’s method to produce a meta-analysis P-value for the associa-
tion of each TF-target gene module in HD mouse models.
We used quantitative proteomics data from 6-month-old HttQ20/+,
HttQ80/+, HttQ92/+, HttQ111/+, HttQ140/+, and HttQ175/+ mice (n = 8
per group) (Langfelder et al, 2016). We characterized proteins whose
abundance was correlated with Htt CAG length in the striatum of
6-month-old mice, using MaxQuant protein quantities. We then calcu-
lated enrichments of CAG length-correlated proteins (Pearson’s corre-
lation, P < 0.01) for each TF-target gene module with Fisher’s exact
test, separately for proteins whose abundance was positively or nega-
tively correlated with CAG length.
We used the limma R package to fit a linear model to character-
ize differentially expressed genes in each of two microarray datasets
(Hodges et al, 2006; Durrenberger et al, 2015) profiling dorsal stria-
tum of HD cases versus controls, treating sex as a covariate. We
calculated enrichments of the DEGs from each study for TF-target
gene modules. We then combined the enrichment P-values across
the two studies using Fisher’s method to produce a meta-analysis
P-value for the association of each TF-target gene module with HD.
Mouse breeding, genotyping, and microdissection
The B6.HttQ111/+mice (Strain 003456; JAX) used for the ChIP-seq
study have a targeted mutation replacing a portion of mouse Htt
(formerly Hdh) exon 1 with the corresponding portion of human
HTT (formerly IT15) exon 1, including an expanded CAG tract (orig-
inally 109 repeats). Mice used in the present study were on the
C57BL/6J inbred strain background (Langfelder et al, 2016; Ament
et al, 2017). Cohorts of heterozygote and wild-type littermate mice
were generated by crossing B6.HttQ111/+ and B6.Htt+/+ mice. Male
mice were sacrificed at 122  2 days of age (or 16 weeks) and
11 months via a sodium pentobarbital-based euthanasia solution
(Fatal Plus, Henry Schein). Both hemispheres of each animal’s brain
were microdissected on ice into striatum, cortex, and remaining
brain regions. These tissues were snap-frozen and stored in 80°C.
Experiments were approved by an institutional review board in
accordance with NIH animal care guidelines.
Western blot
Male and female HttQ111/+ and wild-type littermates at 4 and
11 months of age were euthanized with sodium pentobarbital and
brains microdissected as described above. Striatal tissue was
disrupted and homogenized in lysis buffer (Cell Signaling Technol-
ogy, #9803) containing protease and phosphatase inhibitors
(Thermo, #78443) using a syringe and 26-ga needle and then soni-
cated twice for five-seconds on ice. Debris was pelleted by centrifug-
ing for 20 min at 13,000 g assay. Protein concentration was
determined by BCA assay (Thermo, #PI23225), and 50 lg of dena-
tured protein was prepared in LDS sample buffer (Invitrogen,
NP0008). For quantitative Western blot analysis, the experimenter
was blinded to both genotype and age and the protein was loaded in
randomized order then run on 10% bis-tris polyacrylamide gels with
MOPS running buffer (Invitrogen, NP0004, NP0001, and NP0302).
Protein was transferred to low-fluorescence PVDF membranes
(Immobilon-FL; Millipore) and total protein quantified for loading
normalization (LiCor, #926-11010; LiCor Odyssey Fc Imager). All
membrane wash steps were performed in tris-buffered saline with
0.05% Tween-20. Membranes were blocked (LiCor #927-50100) for
45 min before incubation in primary antibody against phospho-
SMAD3 (Abcam ab52903; 1:500, 72 h at 4°C) and total SMAD3
(Invitrogen #MA5-15663; 1:500, 72 h at 4°C) prepared in the block-
ing solution with 0.05% Tween-20. Secondary antibodies used were
goat anti-rabbit and goat anti-mouse (LiCor #925-32210, #925-
32211, #925-68070, and #925-68071; 1:150,000) made in blocking
buffer with 0.05% Tween-20 and 0.01% SDS. Quantitation of signal
was performed using Image Studio v5.2 (LiCor) with the experi-
menter remaining blinded to genotype and age. SMAD3 signal was
normalized to total protein stain.
High-resolution X-ChIP-seq
We prepared duplicate ChIP samples for each antibody from
4-month-old HttQ111/+ and from age-matched wild-type mice. For
each ChIP preparation, chromatin DNA was prepared using the
combined striatal tissue from both hemispheres of three mice.
Preliminary experiments suggested that this was the minimal
amount of material required to provide enough material for multiple
IPs. Striata were transferred to a glass dounce on ice and homoge-
nized in cold PBS with protease inhibitors. High-resolution X-ChIP-
seq was performed as described (Skene et al, 2010), with slight
modifications. IPs were performed using Abcam anti-SMAD3 anti-
body ab28379 [ChIP grade] or anti-RNA polymerase II CTD repeat
YSPTSPS antibody [8WG16] [ChIP Grade] ab817. Sequencing
libraries were prepared from the isolated ChIP DNA and from input
DNA controls as previously described (Orsi et al, 2015). Libraries
were sequenced on an Illumina HiSeq 2500 sequencer to a depth of
~17–25 million paired-end 25-bp reads per sample. Sequence reads
have been deposited in GEO, accession GSE88775.
ChIP-seq analysis
Sequencing reads were aligned to the mouse genome (mm9) using
bowtie2 (Langmead & Salzberg, 2012). Peak-calling on each sample
was performed with MACS v2.1 (Zhang et al, 2008), scaling each
library to the size of the input DNA sequence library to improve
comparability between samples. We retained peak regions with a
significant MACS P-value (FDR < 0.01 and a read count ≥ 10 in at
least two of the individual ChIP samples). Enrichment of the SMAD3
motif (JASPAR CORE MA0513.1) was performed with CentriMo
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(Bailey & Machanick, 2012), using the 250-bp regions around peak
summits obtained by running MACS on the combined reads from all
the samples. Peaks were mapped to genes using the chipenrich R
package (Welch et al, 2014), and genes were ranked by the number
of peaks within 10 kb of each gene’s transcription start sites. Gene
Ontology enrichment analysis of the top SMAD3 target genes (peak
counts > 2 SD above the mean) was performed using Fisher’s exact
test, using the same set of GO terms used to analyze the computa-
tionally derived TF-target gene modules. Statistical analysis of dif-
ferential occupancy in HttQ111/+ versus wild-type mice was
performed with edgeR (Robinson et al, 2010).
Software and primary data resources
Code for analysis of gene expression, transcriptional regulatory
networks, and ChIP-seq data for this manuscript are publicly avail-
able in the github repository located at https://github.com/seth-ame
nt/hd-trn. BedGraph files and raw sequencing data for SMAD3 and
RNA Pol2 ChIP-seq can be accessed at the GEO repository
GSE88775.
Expanded View for this article is available online.
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